Danish biotechnology company Saniona AB (OMX: SANION), which is focused diseases relating to eating disorders and the central nervous system (CNS), revealed on Tuesday that it has appointed Rami Levin as chief executive officer, effective immediately.
Saniona said Levin is a highly experienced pharmaceutical industry executive who is expected to oversee the company's transition to a fully-fledged biopharmaceutical company with focus on rare diseases. He was appointed by the board of directors in close consultation with the company's founders, Jørgen Drejer and Thomas Feldthus. Levin will be based in Boston.
The decision to appoint Levin was based on his extensive relevant experience in bringing treatments for rare diseases to market, as well as in managing and building organizations in the US. In addition, he brings familiarity with Sweden and Scandinavia in general from previous roles as president, North America at Sobi (Swedish Orphan Biovitrum) and managing director of the Merck Group in Scandinavia.
Also, Jørgen Drejer, current CEO, will continue in the role of chief scientific officer of Saniona.
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
Bain Capital to acquire Mitsubishi Tanabe Pharma in USD3.3bn deal
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease
Johnson & Johnson agrees acquisition of Intra-Cellular Therapies Inc
Neuraxpharm acquires Provigil and Nuvigil to expand CNS portfolio
Nuvation Bio secures NMPA approval for taletrectinib in China
JCR Pharmaceuticals and Modalis Therapeutics advance to next phase of joint gene therapy research
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities